vs

Side-by-side financial comparison of PROGRESS SOFTWARE CORP (PRGS) and Bio-Techne (TECH). Click either name above to swap in a different company.

Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $252.7M, roughly 1.2× PROGRESS SOFTWARE CORP). Bio-Techne runs the higher net margin — 12.8% vs 10.2%, a 2.7% gap on every dollar of revenue. On growth, PROGRESS SOFTWARE CORP posted the faster year-over-year revenue change (17.5% vs -6.4%). Over the past eight quarters, PROGRESS SOFTWARE CORP's revenue compounded faster (17.0% CAGR vs 4.2%).

Progress Software Corporation develops and sells enterprise software products including application development platforms, data connectivity tools, and digital experience solutions. It serves global enterprise clients across finance, healthcare, manufacturing, retail and other sectors, helping organizations build scalable, high-performance business applications and streamline operational workflows.

Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.

PRGS vs TECH — Head-to-Head

Bigger by revenue
TECH
TECH
1.2× larger
TECH
$295.9M
$252.7M
PRGS
Growing faster (revenue YoY)
PRGS
PRGS
+24.0% gap
PRGS
17.5%
-6.4%
TECH
Higher net margin
TECH
TECH
2.7% more per $
TECH
12.8%
10.2%
PRGS
Faster 2-yr revenue CAGR
PRGS
PRGS
Annualised
PRGS
17.0%
4.2%
TECH

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
PRGS
PRGS
TECH
TECH
Revenue
$252.7M
$295.9M
Net Profit
$25.7M
$38.0M
Gross Margin
81.6%
64.6%
Operating Margin
15.2%
18.4%
Net Margin
10.2%
12.8%
Revenue YoY
17.5%
-6.4%
Net Profit YoY
2144.6%
68.3%
EPS (diluted)
$0.59
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRGS
PRGS
TECH
TECH
Q4 25
$252.7M
$295.9M
Q3 25
$249.8M
Q2 25
$237.4M
$317.0M
Q1 25
$238.0M
$316.2M
Q4 24
$215.0M
$297.0M
Q3 24
$178.7M
$289.5M
Q2 24
$175.1M
$306.1M
Q1 24
$184.7M
$303.4M
Net Profit
PRGS
PRGS
TECH
TECH
Q4 25
$25.7M
$38.0M
Q3 25
$19.4M
Q2 25
$17.0M
$-17.7M
Q1 25
$10.9M
$22.6M
Q4 24
$1.1M
$34.9M
Q3 24
$28.5M
$33.6M
Q2 24
$16.2M
$40.6M
Q1 24
$22.6M
$49.1M
Gross Margin
PRGS
PRGS
TECH
TECH
Q4 25
81.6%
64.6%
Q3 25
81.0%
Q2 25
80.1%
62.7%
Q1 25
80.6%
67.9%
Q4 24
83.0%
65.3%
Q3 24
83.7%
63.2%
Q2 24
81.7%
66.4%
Q1 24
82.2%
67.4%
Operating Margin
PRGS
PRGS
TECH
TECH
Q4 25
15.2%
18.4%
Q3 25
17.6%
Q2 25
16.3%
-7.5%
Q1 25
13.6%
12.2%
Q4 24
10.0%
16.0%
Q3 24
22.6%
13.8%
Q2 24
15.5%
15.0%
Q1 24
19.0%
22.1%
Net Margin
PRGS
PRGS
TECH
TECH
Q4 25
10.2%
12.8%
Q3 25
7.8%
Q2 25
7.2%
-5.6%
Q1 25
4.6%
7.1%
Q4 24
0.5%
11.7%
Q3 24
15.9%
11.6%
Q2 24
9.2%
13.3%
Q1 24
12.3%
16.2%
EPS (diluted)
PRGS
PRGS
TECH
TECH
Q4 25
$0.59
$0.24
Q3 25
$0.44
Q2 25
$0.39
$-0.11
Q1 25
$0.24
$0.14
Q4 24
$0.01
$0.22
Q3 24
$0.65
$0.21
Q2 24
$0.37
$0.26
Q1 24
$0.51
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRGS
PRGS
TECH
TECH
Cash + ST InvestmentsLiquidity on hand
$94.8M
$172.9M
Total DebtLower is stronger
$1.4B
$260.0M
Stockholders' EquityBook value
$478.3M
$2.0B
Total Assets
$2.5B
$2.5B
Debt / EquityLower = less leverage
2.93×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRGS
PRGS
TECH
TECH
Q4 25
$94.8M
$172.9M
Q3 25
$99.0M
Q2 25
$102.0M
$162.2M
Q1 25
$124.2M
$140.7M
Q4 24
$118.1M
$177.5M
Q3 24
$232.7M
$187.5M
Q2 24
$190.4M
$152.9M
Q1 24
$133.2M
$145.3M
Total Debt
PRGS
PRGS
TECH
TECH
Q4 25
$1.4B
$260.0M
Q3 25
$1.4B
Q2 25
$1.5B
$346.0M
Q1 25
$1.5B
$330.0M
Q4 24
$1.5B
$300.0M
Q3 24
$300.0M
Q2 24
$319.0M
Q1 24
$389.0M
Stockholders' Equity
PRGS
PRGS
TECH
TECH
Q4 25
$478.3M
$2.0B
Q3 25
$477.7M
Q2 25
$452.7M
$1.9B
Q1 25
$431.8M
$2.0B
Q4 24
$438.8M
$2.1B
Q3 24
$425.6M
$2.1B
Q2 24
$401.7M
$2.1B
Q1 24
$461.7M
$2.0B
Total Assets
PRGS
PRGS
TECH
TECH
Q4 25
$2.5B
$2.5B
Q3 25
$2.4B
Q2 25
$2.4B
$2.6B
Q1 25
$2.5B
$2.6B
Q4 24
$2.5B
$2.7B
Q3 24
$1.6B
$2.7B
Q2 24
$1.6B
$2.7B
Q1 24
$1.5B
$2.7B
Debt / Equity
PRGS
PRGS
TECH
TECH
Q4 25
2.93×
0.13×
Q3 25
2.97×
Q2 25
3.22×
0.18×
Q1 25
3.50×
0.16×
Q4 24
3.48×
0.14×
Q3 24
0.14×
Q2 24
0.15×
Q1 24
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRGS
PRGS
TECH
TECH
Operating Cash FlowLast quarter
$62.8M
Free Cash FlowOCF − Capex
$59.9M
FCF MarginFCF / Revenue
23.7%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
2.44×
TTM Free Cash FlowTrailing 4 quarters
$229.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRGS
PRGS
TECH
TECH
Q4 25
$62.8M
Q3 25
$73.4M
Q2 25
$30.0M
$98.2M
Q1 25
$68.9M
$41.1M
Q4 24
$19.7M
$84.3M
Q3 24
$57.7M
$63.9M
Q2 24
$63.7M
$75.5M
Q1 24
$70.5M
$81.0M
Free Cash Flow
PRGS
PRGS
TECH
TECH
Q4 25
$59.9M
Q3 25
$72.4M
Q2 25
$29.5M
$93.3M
Q1 25
$67.7M
$31.0M
Q4 24
$16.8M
$77.5M
Q3 24
$56.6M
$54.7M
Q2 24
$62.7M
$57.5M
Q1 24
$70.2M
$64.5M
FCF Margin
PRGS
PRGS
TECH
TECH
Q4 25
23.7%
Q3 25
29.0%
Q2 25
12.4%
29.4%
Q1 25
28.4%
9.8%
Q4 24
7.8%
26.1%
Q3 24
31.7%
18.9%
Q2 24
35.8%
18.8%
Q1 24
38.0%
21.3%
Capex Intensity
PRGS
PRGS
TECH
TECH
Q4 25
1.1%
Q3 25
0.4%
Q2 25
0.2%
1.5%
Q1 25
0.5%
3.2%
Q4 24
1.3%
2.3%
Q3 24
0.6%
3.2%
Q2 24
0.5%
5.9%
Q1 24
0.2%
5.4%
Cash Conversion
PRGS
PRGS
TECH
TECH
Q4 25
2.44×
Q3 25
3.78×
Q2 25
1.76×
Q1 25
6.30×
1.82×
Q4 24
17.13×
2.42×
Q3 24
2.03×
1.90×
Q2 24
3.93×
1.86×
Q1 24
3.11×
1.65×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRGS
PRGS

Maintenanceand Services$187.5M74%
Share File Acquisition$67.5M27%

TECH
TECH

Diagnostics And Spatial Biology$81.2M27%
EMEA Excluding UK$75.4M25%
Other$42.4M14%
Instruments$29.6M10%
APAC Excluding Greater China$22.7M8%
Services$22.3M8%
GB$13.7M5%
Royalty$8.5M3%

Related Comparisons